- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05198882
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy (EPILITT)
October 3, 2022 updated by: Assistance Publique - Hôpitaux de Paris
Laser Induced Interstitial Thermal Therapy (LITT) is a "minimally invasive" procedure that uses the heat generated by a laser light (65°) to destroy brain lesions by coagulation leading to lesion necrosis under real-time MRI monitoring.
The laser optical fiber is implanted into the lesion using stereotaxy.
This technique, which can be performed under local anesthesia and on an outpatient basis, proved its efficacy and safety in the treatment of brain metastases for the first time in the world in 2006 (A.
Carpentier et al, 2008, 2011).
Since then, more than 5,000 patients have been treated in the USA, including for epileptogenic lesions (FDA device and CE cleared).
Our goal is to evaluate LITT on lesions with drug-resistant epilepsy for which surgical resection is impossible.
No therapeutic trial evaluating LITT in this indication has been performed to date.
It is therefore necessary to study its feasibility and tolerance.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bertrand Mathon, MD
- Phone Number: 01 84 82 73 63
- Email: bertrand.mathon@aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Hopital Pitie Salpetriere
-
Contact:
- Bertrand Mathon, MD
- Phone Number: +33 01 84 82 73 63
- Email: bertrand.mathon@aphp.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years and < 80 years
- Patient with a medically unbalanced partial epilepsy
- Patient with a lesional image(s) in morphological MRI responsible for epilepsy based on clinical and electrophysiological assessment, +/- PET +/- SPECT +/- MEG +/- sEEG
- Patients for whom scheduled neurosurgical treatment with craniotomy appears difficult: Deep lesions, eloquent region lesions, patient reluctance to perform surgery.
- Endorsement of the Multidisciplinary Meeting of Neuro-epileptology
- Patient affiliated with a social security scheme
- Patient who has signed prior, free and informed consent
Exclusion Criteria:
- Pharmacosensitive epilepsy
- Patient with poor adherence to medication, or with psychological disorders
- Patients under legal protection
- Patient with a contraindication to MRI (metal shards, known allergy to gadolinium, etc.)
- Anticoagulant and antiplatelet therapy underway, cannot be stopped.
- Severe and unbalanced psychiatric disorders
- Pregnant women. Women of childbearing age should use oral contraception throughout the study.
- Allergy to local anaesthetics / general anaesthesia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LITT technology
Laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
|
One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking).
The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of post-surgical complication of grade greater or equal to 2 according to Mathon and al classification
Time Frame: Day 30 post-operative
|
To assess the safety and feasibility of laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
|
Day 30 post-operative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seizure freedom evaluated with Engel classification
Time Frame: Post surgery : Month 1, Month 3, Month 6, Month 12
|
Evaluate the clinical epileptic efficacy of treatment based by the ILAE and Engel classifications.
|
Post surgery : Month 1, Month 3, Month 6, Month 12
|
Seizure freedom evaluated with ILAE (International League Against Epilepsy) classification
Time Frame: Post surgery : Month 1, Month 3, Month 6, Month 12
|
Evaluate the clinical epileptic efficacy of treatment based by the ILAE and Engel classifications.
|
Post surgery : Month 1, Month 3, Month 6, Month 12
|
Number of seizure per patient
Time Frame: Post surgery : Month 1, Month 3, Month 6, Month 12
|
Evaluate the frequency of seizure
|
Post surgery : Month 1, Month 3, Month 6, Month 12
|
Number of patient with at least one seizure with complex partial seizure
Time Frame: Post surgery : Month 1, Month 3, Month 6, Month 12
|
Evaluate the intensity of seizure after treatment.
|
Post surgery : Month 1, Month 3, Month 6, Month 12
|
Number of patient at least one modification of anti-epileptic treatment
Time Frame: Post surgery : Month 1, Month 3, Month 6, Month 12
|
Evaluation of clinical efficacy of treatment
|
Post surgery : Month 1, Month 3, Month 6, Month 12
|
Mean change of quantification of the number of interictal peaks over 30 minutes evaluated at surface EEG compared to the pre surgery surface EEG
Time Frame: Post surgery : Month 3, Month 6, Month 12
|
Electrophysiological epileptic efficacy
|
Post surgery : Month 3, Month 6, Month 12
|
Mean change neuropsychological scores
Time Frame: Post surgery : Month 12
|
Evaluate the effect on cognition by a postoperative neuropsychological evaluation, compared with the pre-treatment neuropsychological evaluation.The neuro-psychological test will be selected according to the location of the lesion/focus
|
Post surgery : Month 12
|
Mean change in Quality of Life in Epilepsy (QOLIE-31) scores
Time Frame: Post surgery : Month 6, Month 12
|
Evaluate the effect on quality of life by comparing the preoperative assessment with the postoperative assessments.
|
Post surgery : Month 6, Month 12
|
Incidence of adverse events
Time Frame: Day of surgery, Day 2, Day 7, Day 30 post-operative
|
Evaluate the clinical tolerance of the procedure.
|
Day of surgery, Day 2, Day 7, Day 30 post-operative
|
Mean consumption of anti-epileptic drugs and epilepsy-related care
Time Frame: Post surgery : Month 12
|
To assess the medico-economic impact of the treatment
|
Post surgery : Month 12
|
Mean of major and minor axis measurements evaluated by measuring post-treatment morphological MRI images corresponding to induced necrosis in T1 gadolinium SPGR MRI
Time Frame: Month 1, Month 3, Month 12
|
Evaluate the radiological epileptic efficacy of treatment
|
Month 1, Month 3, Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 4, 2022
Primary Completion (Anticipated)
September 15, 2023
Study Completion (Anticipated)
August 15, 2024
Study Registration Dates
First Submitted
December 6, 2021
First Submitted That Met QC Criteria
January 17, 2022
First Posted (Actual)
January 20, 2022
Study Record Updates
Last Update Posted (Actual)
October 4, 2022
Last Update Submitted That Met QC Criteria
October 3, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP200097
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Laser technology for intracerebral thermocoagulation
-
Vanderbilt University Medical CenterCompletedNephrolithiasisUnited States
-
Federal University of Espirito SantoEnrolling by invitationUpper Limb Amputation at the HandBrazil
-
The S.N. Fyodorov Eye Microsurgery State InstitutionUnknownRhegmatogenous Retinal DetachmentRussian Federation
-
Karolinska InstitutetCompletedType 2 Diabetes Mellitus | Dietary HabitsSweden
-
Jeonbuk Provincial Maeumsarang HospitalCompleted
-
Mary LacyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting
-
University of RochesterCompletedAcne Scars - Mixed Atrophic and HypertrophicUnited States
-
Nemours Children's ClinicNational Institute of General Medical Sciences (NIGMS)CompletedAsthma in ChildrenUnited States
-
University of British ColumbiaVancouver Coastal Health Research Institute; GF Strong Rehabilitation CentreCompletedUnilateral Trans Tibial/Femoral Lower Limb AmputationCanada
-
Durrie VisionAlcon ResearchUnknown